Korean Medication Algorithm Project for Bipolar Disorder 2022:Mixed Features / 신경정신의학
Won KIM; Won-Myong BAHK; Young-Sup WOO; Jong-Hyun JEONG; Jeong-Seok SEO; IL-Han CHOO; Chan-Mo YANG; Jung-Goo LEE; Se-Hoon SHIM; Bo-Hyun YOON; Sung-Yong PARK; InKi SOHN; Moon-Doo KIM; Myung-Hun JUNG; Duk-In JON.
Journal of Korean Neuropsychiatric Association
; : 133-142, 2022.
Artículo
en Inglés
| WPRIM | ID: wpr-926002
Objectives@#Treatment guidelines or an algorithm can help clinicians implement better practices and clinical decisions. Therefore, the Korean Medication Algorithm Project for Bipolar Disorder 2022 (KMAP-BP 2022) was revised again through a consensus of expert opinion. The diagnosis and treatment of mixed features are not simple, and there are many things to discuss. We describe the preferences and recommendations from KMAP-BP 2022 for the treatment of mood episodes with mixed features. @*Methods@#We revised the KMAP-BP 2018 questionnaire and conducted the survey with expert clinicians. Out of ninety-three members of the review committee, eighty-seven completed the survey. We analyzed the answers, discussed the data, and held a clinician hearing. @*Results@#In first-step strategies for mixed features with more manic symptoms, a combination of a mood stabilizer and an atypical antipsychotic is the treatment of choice. Mood stabilizer monotherapy and atypical antipsychotic monotherapy are preferred strategies. For mixed features with more depressive symptoms, a combination of mood stabilizer and atypical antipsychotic, a combination of atypical antipsychotic and lamotrigine (LMT), atypical antipsychotic monotherapy, a combination of mood stabilizer and LMT, and mood stabilizer monotherapy are preferred. For mixed features with similar manic symptoms and depressive symptoms, a combination of mood stabilizer and atypical antipsychotic, atypical antipsychotic monotherapy, and mood stabilizer monotherapy are preferred. @*Conclusion@#For mixed features, a combination of mood stabilizer and atypical antipsychotic is generally preferred, and LMT is preferred for depressive symptoms. Compared with KMAP-BP 2018, more diverse strategies and drugs are being attempted for the treatment of mixed features.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados